Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis

Phosphodiesterase type 5 (PDE5) inhibitors are recommended for patients with erectile dysfunction by American Urological Association and European Association Urology guidelines. However, recent researches have shown that PDE5 inhibitors may lead to increased melanoma risk. Thus, we aimed to explore...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Shijian, Zhou, Liang, Liu, Qinyu, He, Qing, Liao, Banghua, Wei, Xin, Li, Hong, Wang, Kunjie, Zhu, Yuchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779753/
https://www.ncbi.nlm.nih.gov/pubmed/29504984
http://dx.doi.org/10.1097/MD.0000000000009601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779753/
https://www.ncbi.nlm.nih.gov/pubmed/29504984
http://dx.doi.org/10.1097/MD.0000000000009601

Ejemplares similares